It is a support menu from here.
Main Menu
Product Information
Joint Development of Solid Support for Oligonucleotide Synthesis, used in Synthesis of Antisense Drugs
11.26.2004
Nitto Denko (based in Ibaraki, Osaka; president, Masamichi Takemoto) has developed a new high performance solid support for the synthesis of antisense drugs in a joint development with Isis Pharmaceuticals, Inc., a US company that was the first in the world to succeed in bringing an antisense drug (a gene therapy) to market.
This newly developed product is essential in synthesizing oligonucleotides such as DNA and RNA-based gene therapies, and enables high-grade, high-yield synthesis of oligonucleotides.
Development Background
In recent years, the life science field has focused on gene therapies that deliver genes and portions of genes (oligonucleotides) within a person’s body with the objective of curing diseases.
Antisense drugs are one of the most common gene therapies, and it genetically inhibits the synthesis of the protein that caused the disease. It is expected to be effective in curing diseases such as cancer.
Also, antisense drugs directly act on nucleic acid, the intended target, and are more effective with lower toxicity than the conventional low molecular weight pharmacological agents.
In light of the promise of this drug, Nitto Denko and Nitto Denko Technical Corporation, a dedicated research and development facility in the US, developed a high-performance cross-linked polystyrene beads for the synthesis of oligonucleotides in a joint development with Isis.
_Englarged image of solid support (polymer beads) _Flow of genetic information and antisense therapy.
Image of oligonucleotide synthesis on surface of polymer bead and inside polymer bead
Characteristics
Proprietary bead design (composition, structure, etc.) enabled the high-grade and high-yield synthesis of oligonucleotides
Future Business Development
The polymer beads jointly developed with Isis will be marketed through Nitto Denko’s wholly-owned US subsidiary, Kinovate Life Sciences, Inc. (established in January 2004).
The Company plans to expand into the next-generation gene therapy such as polymer beads for the synthesis of siRNA
Reference
Nitto Denko Technical Corporation
Location: Oceanside, California, USA (San Diego suburb)
Website: http://www.ndtcorp.com/
Established: October 2000
Stakeholder: Nitto Denko Corporation, 100%
Employees: 32
Research Topics: Bioscience (gene carriers, peptide transdermal absorption and others), advanced technology (synthesis and evaluation of organic materials used in optical communication handset devices)
Kinovate Life Sciences, Inc.
Location: Oceanside, California, USA (San Diego suburb); shares premises with Nitto Denko Technical Corporation
Established: January 2004
Stakeholder: Nitto Denko Corporation, 100%
Employees: 2
Research Topics: Sale and marketing of state-of-the-art life science technology developed by Nitto Denko Technical Corporation
Contuct Us
Footer Area
